Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940230 | 0.89 | NR1I2 (0.55) | NR1I2CYP2E1GLS | |
| SCHEMBL12909646 | 0.89 | NR1I2 (0.55) | NR1I2CYP2E1GLS | |
| SCHEMBL12945482 | 0.89 | NR1I2 (0.40) | NR1I2CYP2E1GBA1 | |
| SCHEMBL12945479 | 0.88 | NR1I2 (0.41) | NR1I2CYP2E1 | |
| SCHEMBL12945280 | 0.87 | NR1I2 (0.39) | NR1I2CYP2E1 | |
| SCHEMBL12945253 | 0.87 | NR1I2 (0.39) | NR1I2CYP2E1 | |
| SCHEMBL12945310 | 0.87 | NR1I2 (0.40) | NR1I2CYP2E1GBA1HRH3 | |
| SCHEMBL12945511 | 0.87 | NR1I2 (0.38) | NR1I2CYP2E1 | |
| SCHEMBL12945803 | 0.87 | NR1I2 (0.38) | NR1I2CYP2E1 | |
| SCHEMBL12945505 | 0.86 | NR1I2 (0.38) | NR1I2CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | NR1I2 88/4885CYP2E1 6/4885GLS 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.